id: NEW:immune_checkpoint_inhibitor_plus_chemotherapy_to_NEW:progression_free_survival_advanced_gej_cancer
name: Immune Checkpoint Inhibitor Plus Chemotherapy Treatment â†’ Progression-Free Survival in Advanced
  Gastric/Gastroesophageal Junction Cancer
from_node:
  node_id: NEW:immune_checkpoint_inhibitor_plus_chemotherapy
  node_name: Immune Checkpoint Inhibitor Plus Chemotherapy Treatment
to_node:
  node_id: NEW:progression_free_survival_advanced_gej_cancer
  node_name: Progression-Free Survival in Advanced Gastric/Gastroesophageal Junction Cancer
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: ICI therapy reactivates exhausted T-cells in the tumor microenvironment'
- 'Step 2: Enhanced immune surveillance prevents tumor cell proliferation and spread'
- 'Step 3: Chemotherapy directly kills rapidly dividing cancer cells'
- 'Step 4: Synergistic effect of immunotherapy and chemotherapy delays disease progression'
- 'Step 5: Extended time before tumor growth or metastasis (progression-free survival)'
evidence:
  quality_rating: A
  n_studies: 5
  primary_citation: 'Lianghui Zhang et al. 2024. "Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line
    Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis."
    https://doi.org/10.1177/15330338241273286'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 5 randomized controlled trials
  - Studies involving 2,814 patients with advanced G/GEJ cancer
  - Trials comparing ICI plus chemotherapy versus chemotherapy alone as first-line treatment
  doi: 10.1177/15330338241273286
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Combination of immune checkpoint inhibitors with chemotherapy as first-line treatment significantly
  improves progression-free survival in patients with advanced gastric or gastroesophageal junction cancer
  compared to chemotherapy alone, with a 21% reduction in hazard of progression or death.
quantitative_effects:
  effect_size:
    value: 0.79
    type: hazard_ratio
    ci_lower: 0.63
    ci_upper: 0.99
  p_value: 0.001
  sample_size: 2814
structural_competency:
  equity_implications: Progression-free survival improvements require sustained access to treatment and
    monitoring. Structural barriers including insurance coverage gaps, treatment costs, and access to
    specialized oncology care may create inequities in who benefits from these therapeutic advances.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.897073'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
